Characterization of the effect of chronic administration of a calcium-sensing receptor antagonist, ronacaleret, on renal calcium excretion and serum calcium in postmenopausal women

Stephen Caltabiano, Colin T. Dollery, Mohammad Hossain, Milena T. Kurtinecz, John P. Desjardins, Murray J. Favus, Rajiv Kumar, Lorraine A. Fitzpatrick

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Ronacaleret is an orally-active calcium-sensing receptor (CaSR) antagonist that has the potential for therapeutic utility in the stimulation of PTH release, notably as a bone anabolic agent comparable to recombinant human PTH(1-34) (rhPTH(1-34)). A recent study has shown that, despite the ability to increase circulating PTH levels in postmenopausal women in a dose-dependent manner, minimal effects of ronacaleret on bone mineral density have been observed. Therefore, the purpose of this study was to characterize the PTH profile as well as calcium metabolism parameters as a marker of PTH biological activity following the administration of ronacaleret or rhPTH(1-34). Administration of ronacaleret led to lower peak levels of PTH than were observed with rhPTH(1-34), however, greater total PTH exposure was observed. Further, chronic administration of either agent was associated with increases in urinary calcium excretion and serum calcium levels, with the magnitude of the changes following ronacaleret significantly greater than that for rhPTH(1-34). The greater magnitude of effects observed with ronacaleret is likely due to the greater total PTH exposure, and is potentially reflective of a state comparable to mild hyperparathyroidism. It is not clear whether the administration of all calcilytics would lead to a similar result, or is due to characteristics specific to ronacaleret.

Original languageEnglish (US)
Pages (from-to)154-162
Number of pages9
JournalBone
Volume56
Issue number1
DOIs
StatePublished - Sep 2013

Fingerprint

Calcium-Sensing Receptors
Calcium
Parathyroid Hormone
Serum
Anabolic Agents
Hyperparathyroidism
ronacaleret
Renal Elimination
Bone Density
Biomarkers
Bone and Bones

Keywords

  • Calcilytic
  • Calcium homeostasis
  • Calcium-sensing receptor
  • Kidney
  • Parathyroid hormone
  • Postmenopausal osteoporosis

ASJC Scopus subject areas

  • Physiology
  • Endocrinology, Diabetes and Metabolism
  • Histology

Cite this

Characterization of the effect of chronic administration of a calcium-sensing receptor antagonist, ronacaleret, on renal calcium excretion and serum calcium in postmenopausal women. / Caltabiano, Stephen; Dollery, Colin T.; Hossain, Mohammad; Kurtinecz, Milena T.; Desjardins, John P.; Favus, Murray J.; Kumar, Rajiv; Fitzpatrick, Lorraine A.

In: Bone, Vol. 56, No. 1, 09.2013, p. 154-162.

Research output: Contribution to journalArticle

Caltabiano, Stephen ; Dollery, Colin T. ; Hossain, Mohammad ; Kurtinecz, Milena T. ; Desjardins, John P. ; Favus, Murray J. ; Kumar, Rajiv ; Fitzpatrick, Lorraine A. / Characterization of the effect of chronic administration of a calcium-sensing receptor antagonist, ronacaleret, on renal calcium excretion and serum calcium in postmenopausal women. In: Bone. 2013 ; Vol. 56, No. 1. pp. 154-162.
@article{a174e25587034c9583fa2c5a07f9595a,
title = "Characterization of the effect of chronic administration of a calcium-sensing receptor antagonist, ronacaleret, on renal calcium excretion and serum calcium in postmenopausal women",
abstract = "Ronacaleret is an orally-active calcium-sensing receptor (CaSR) antagonist that has the potential for therapeutic utility in the stimulation of PTH release, notably as a bone anabolic agent comparable to recombinant human PTH(1-34) (rhPTH(1-34)). A recent study has shown that, despite the ability to increase circulating PTH levels in postmenopausal women in a dose-dependent manner, minimal effects of ronacaleret on bone mineral density have been observed. Therefore, the purpose of this study was to characterize the PTH profile as well as calcium metabolism parameters as a marker of PTH biological activity following the administration of ronacaleret or rhPTH(1-34). Administration of ronacaleret led to lower peak levels of PTH than were observed with rhPTH(1-34), however, greater total PTH exposure was observed. Further, chronic administration of either agent was associated with increases in urinary calcium excretion and serum calcium levels, with the magnitude of the changes following ronacaleret significantly greater than that for rhPTH(1-34). The greater magnitude of effects observed with ronacaleret is likely due to the greater total PTH exposure, and is potentially reflective of a state comparable to mild hyperparathyroidism. It is not clear whether the administration of all calcilytics would lead to a similar result, or is due to characteristics specific to ronacaleret.",
keywords = "Calcilytic, Calcium homeostasis, Calcium-sensing receptor, Kidney, Parathyroid hormone, Postmenopausal osteoporosis",
author = "Stephen Caltabiano and Dollery, {Colin T.} and Mohammad Hossain and Kurtinecz, {Milena T.} and Desjardins, {John P.} and Favus, {Murray J.} and Rajiv Kumar and Fitzpatrick, {Lorraine A.}",
year = "2013",
month = "9",
doi = "10.1016/j.bone.2013.05.021",
language = "English (US)",
volume = "56",
pages = "154--162",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Characterization of the effect of chronic administration of a calcium-sensing receptor antagonist, ronacaleret, on renal calcium excretion and serum calcium in postmenopausal women

AU - Caltabiano, Stephen

AU - Dollery, Colin T.

AU - Hossain, Mohammad

AU - Kurtinecz, Milena T.

AU - Desjardins, John P.

AU - Favus, Murray J.

AU - Kumar, Rajiv

AU - Fitzpatrick, Lorraine A.

PY - 2013/9

Y1 - 2013/9

N2 - Ronacaleret is an orally-active calcium-sensing receptor (CaSR) antagonist that has the potential for therapeutic utility in the stimulation of PTH release, notably as a bone anabolic agent comparable to recombinant human PTH(1-34) (rhPTH(1-34)). A recent study has shown that, despite the ability to increase circulating PTH levels in postmenopausal women in a dose-dependent manner, minimal effects of ronacaleret on bone mineral density have been observed. Therefore, the purpose of this study was to characterize the PTH profile as well as calcium metabolism parameters as a marker of PTH biological activity following the administration of ronacaleret or rhPTH(1-34). Administration of ronacaleret led to lower peak levels of PTH than were observed with rhPTH(1-34), however, greater total PTH exposure was observed. Further, chronic administration of either agent was associated with increases in urinary calcium excretion and serum calcium levels, with the magnitude of the changes following ronacaleret significantly greater than that for rhPTH(1-34). The greater magnitude of effects observed with ronacaleret is likely due to the greater total PTH exposure, and is potentially reflective of a state comparable to mild hyperparathyroidism. It is not clear whether the administration of all calcilytics would lead to a similar result, or is due to characteristics specific to ronacaleret.

AB - Ronacaleret is an orally-active calcium-sensing receptor (CaSR) antagonist that has the potential for therapeutic utility in the stimulation of PTH release, notably as a bone anabolic agent comparable to recombinant human PTH(1-34) (rhPTH(1-34)). A recent study has shown that, despite the ability to increase circulating PTH levels in postmenopausal women in a dose-dependent manner, minimal effects of ronacaleret on bone mineral density have been observed. Therefore, the purpose of this study was to characterize the PTH profile as well as calcium metabolism parameters as a marker of PTH biological activity following the administration of ronacaleret or rhPTH(1-34). Administration of ronacaleret led to lower peak levels of PTH than were observed with rhPTH(1-34), however, greater total PTH exposure was observed. Further, chronic administration of either agent was associated with increases in urinary calcium excretion and serum calcium levels, with the magnitude of the changes following ronacaleret significantly greater than that for rhPTH(1-34). The greater magnitude of effects observed with ronacaleret is likely due to the greater total PTH exposure, and is potentially reflective of a state comparable to mild hyperparathyroidism. It is not clear whether the administration of all calcilytics would lead to a similar result, or is due to characteristics specific to ronacaleret.

KW - Calcilytic

KW - Calcium homeostasis

KW - Calcium-sensing receptor

KW - Kidney

KW - Parathyroid hormone

KW - Postmenopausal osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=84879547184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879547184&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2013.05.021

DO - 10.1016/j.bone.2013.05.021

M3 - Article

VL - 56

SP - 154

EP - 162

JO - Bone

JF - Bone

SN - 8756-3282

IS - 1

ER -